SCHEMBL6726808

SCHEMBL6726808

COCCN(CCP(CCOC)CCOC)CCP(CCOC)CCOC

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6726807 0.87 MEN1 (0.31) MEN1KMT2A
SCHEMBL4967863 0.86 PIK3CD (0.30) PIK3CDMEN1KMT2A
SCHEMBL20267488 0.84 PIK3CD (0.31) PIK3CDMEN1KMT2A
SCHEMBL4928943 0.82
SCHEMBL20267861 0.82 PIK3CD (0.30) PIK3CDMEN1KMT2A
SCHEMBL9501900 0.79
SCHEMBL1292539 0.79 PIK3CD (0.43) PIK3CDMEN1KMT2A
SCHEMBL20268074 0.78 ALDH1A1 (0.46)
SCHEMBL4966983 0.78
SCHEMBL20267698 0.78 PIK3CD (0.33) PIK3CDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8182789-B2 Intermediate compound of technetium nitride complex for radiodiagnostic imaging NIHON MEDI-PHYSICS CO., LTD. (JP) 2012-05-22 US disclosed
US-8182789-B2 Intermediate compound of technetium nitride complex for radiodiagnostic imaging NIHON MEDI-PHYSICS CO., LTD. (JP) 2012-05-22 US disclosed
US-20100160615-A1 INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING NIHON MED-PHYSICS CO., LTD. (JP) 2010-06-24 US disclosed
US-20100160615-A1 INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING NIHON MED-PHYSICS CO., LTD. (JP) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160615-A1 INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING MEN1, NCDN, C1R PIK3CD 502/4885MEN1 1/4885KMT2A 4603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.